Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
3.29 EUR | +0.61% |
|
-1.02% | +36.86% |
Jun. 06 | CLARIANE : Integrating the above-expectation mid-term guidance | ![]() |
May. 30 | Clariane: Leima Valeurs exceeds 5% of capital & voting rights | CF |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+35.11% | 377M | B+ | ||
+24.66% | 88.38B | C+ | ||
-21.76% | 77.56B | B- | ||
+8.45% | 28.74B | C+ | ||
+7.94% | 18.45B | A- | ||
-13.50% | 16.57B | B | ||
+77.51% | 13.65B | C- | ||
+76.96% | 13.06B | C+ | ||
+4.72% | 12.61B | A- | ||
+36.67% | 12.56B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CLARI Stock
- Ratings Clariane SE